JMP Securities Initiates Coverage On OptimizeRx with Market Outperform Rating, Announces Price Target of $15
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Constantine Davides initiates coverage on OptimizeRx (NASDAQ:OPRX) with a Market Outperform rating and a price target of $15.
April 04, 2024 | 9:02 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
OptimizeRx receives a Market Outperform rating from JMP Securities with a price target of $15.
The initiation of coverage by JMP Securities with a Market Outperform rating and a specific price target of $15 is a positive signal to investors, indicating a bullish outlook on OptimizeRx's stock. This could lead to increased investor interest and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100